Johnson & Johnson (NYSE: JNJ) is a company that may look a lot different over the next several years. Top-selling drug Stelara is facing a patent cliff this year, the company has just spun off one of its business units, and there's no certainty that its legal issues will go away, either.

Here's a look at some of the opportunities and risks for the business, and whether it's a good time to add shares of Johnson & Johnson to your portfolio.

One of the big drawbacks with Johnson & Johnson has been that over the years, while it has been a safe buy, it hasn't generated much growth. Even with a diverse business that included consumer health, pharmaceuticals, and medical devices, its growth rate has been uninspiring, as seen in the chart.

Continue reading

Source Fool.com